A Pilot Randomized Clinical Trial of Intranasal Oxytocin to Promote Weight Loss in Individuals With Hypothalamic Obesity
Open Access
- 6 March 2023
- journal article
- research article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (5) , bvad037
Abstract
Context: Hypothalamic obesity is a rare, treatment-resistant form of obesity. In preliminary studies, the hypothalamic hormone oxytocin (OXT) has shown promise as a potential weight loss therapy. Objective: To determine whether 8 weeks of intranasal OXT (vs 8 weeks of placebo) promotes weight loss in children, adolescents, and young adults with hypothalamic obesity. Methods: This randomized, double-blind, placebo-controlled, crossover pilot trial (NCT02849743), conducted at an outpatient academic medical center, included patients aged 10 to 35 years with hypothalamic obesity from hypothalamic/pituitary tumors. Participants received intranasal OXT (Syntocinon, 40 USP units/mL, 4 IU/spray) vs excipient-matched placebo, 16 to 24 IU 3 times daily at mealtimes. Weight loss attributable to OXT vs placebo and safety (adverse events) were assessed. Results: Of 13 individuals randomized (54% female, 31% pre-pubertal, median age 15.3 years, IQR 13.3-20.6), 10 completed the entire study. We observed a nonsignificant within-subject weight change of −0.6 kg (95% CI: −2.7, 1.5) attributable to OXT vs placebo. A subset (2/18 screened, 5/13 randomized) had prolonged QTc interval on electrocardiography prior to screening and/or in both treatment conditions. Overall, OXT was well-tolerated, and adverse events (epistaxis and nasal irritation, headache, nausea/vomiting, and changes in heart rate, blood pressure, and QTc interval) were similar between OXT and placebo. In exploratory analyses, benefits of OXT for anxiety and impulsivity were observed. Conclusion: In this pilot study in hypothalamic obesity, we did not detect a significant impact of intranasal OXT on body weight. OXT was well-tolerated, so future larger studies could examine different dosing, combination therapies, and potential psychosocial benefits.Keywords
Funding Information
- Doris Duke Clinical Scientist Development Award
This publication has 76 references indexed in Scilit:
- Treatment of Obesity and Diabetes Using Oxytocin or Analogs in Patients and Mouse ModelsPLOS ONE, 2013
- A review of safety, side-effects and subjective reactions to intranasal oxytocin in human researchPsychoneuroendocrinology, 2011
- Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-upEuropean Journal of Endocrinology, 2011
- Weight Reduction in Obese Adolescents With and Without Binge EatingObesity, 2011
- Height Adjustment in Assessing Dual Energy X-Ray Absorptiometry Measurements of Bone Mass and Density in ChildrenThe Journal of Clinical Endocrinology & Metabolism, 2010
- Sniffing neuropeptides: a transnasal approach to the human brainNature Neuroscience, 2002
- On the ability to inhibit simple and choice reaction time responses: A model and a method.Journal of Experimental Psychology: Human Perception and Performance, 1984
- On the ability to inhibit simple and choice reaction time responses: A model and a method.Journal of Experimental Psychology: Human Perception and Performance, 1984
- Effect of Pharmacological Doses of Oxytocin on Insulin Response to Glucose in Normal ManHormone Research, 1984
- Oxytocin Determination by RadioimmunoassayGynecologic and Obstetric Investigation, 1983